Lisata
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for high unmet medical needs, especially in the area of advanced solid tumors. The company focuses on targeted therapies, including its proprietary CendR Platform®, and aims to transform patient lives through its robust pipeline of product candidates. With a mission rooted in scientific innovation and rigorous data, Lisata combines start-up agility with big pharma experience to develop differentiated treatments.
Industries
Nr. of Employees
small (1-50)
Lisata
Patents
Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US-9533010-B2
View DetailsCompositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US-9534202-B2
View DetailsInfarct area perfusion-improving compositions and methods of vascular injury repair
US-9034316-B2
View Details
Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US-9533010-B2
View DetailsCompositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US-9534202-B2
View DetailsInfarct area perfusion-improving compositions and methods of vascular injury repair
US-9034316-B2
View DetailsProducts
Clinical-stage tumor-penetrating peptide therapeutic (development candidate)
An experimental peptide-based therapeutic designed to activate tumor-specific uptake pathways to enhance penetration and accumulation of co-administered anti-cancer agents in solid tumors; evaluated in combination with standard chemotherapy and other modalities across multiple phase 1/2 trials.
CD34+ cell therapy platform
A cell therapy approach based on CD34+ cells with a characterized mechanism of action and a rapid, economical processing workflow intended for therapeutic development.
Clinical-stage tumor-penetrating peptide therapeutic (development candidate)
An experimental peptide-based therapeutic designed to activate tumor-specific uptake pathways to enhance penetration and accumulation of co-administered anti-cancer agents in solid tumors; evaluated in combination with standard chemotherapy and other modalities across multiple phase 1/2 trials.
CD34+ cell therapy platform
A cell therapy approach based on CD34+ cells with a characterized mechanism of action and a rapid, economical processing workflow intended for therapeutic development.
Services
Sponsorship, protocol execution, site management, and oversight of randomized, placebo-controlled oncology studies across multiple regions and institutions.
Partnership engagements with academic groups, industry partners, and external vendors to co-develop programs and apply AI-driven discovery approaches.
Strategic activities to obtain regulatory designations and support clinical development plans for rare and oncology indications.
Sponsorship, protocol execution, site management, and oversight of randomized, placebo-controlled oncology studies across multiple regions and institutions.
Partnership engagements with academic groups, industry partners, and external vendors to co-develop programs and apply AI-driven discovery approaches.
Strategic activities to obtain regulatory designations and support clinical development plans for rare and oncology indications.
Expertise Areas
- Targeted drug delivery for advanced solid tumors
- Oncology clinical trial management (Phase 1–2)
- Platform R&D for tumor penetration and microenvironment modulation
- Biotherapeutic delivery enhancement (immunotherapies, RNA therapeutics)
Key Technologies
- Tumor-penetrating delivery platforms (peptide-mediated)
- Activation of tumor-specific uptake pathways
- Circulating tumor DNA (ctDNA) MRD assays
- CD34+ cell therapy production/process